Intellia Therapeutics
Streamlining registration and requests for gene editing
Pioneering the development of CRISPR/Cas9 genome editing
Co-founded by Jennifer Doudna, 2020 Nobel Prize winner in Chemistry, Intellia Therapeutics is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. The company employs a modular genome editing platform to create diverse in vivo and ex vivo pipelines that span a range of therapeutic indications.
Challenges
| Difficulty finding data across multiple systems | Previous registration took place across SharePoint spreadsheets, emails, and paper, leading to unreliable data and outsize time spent piecing together lineages. |
|---|---|
| Tracking and updating plasmid inventory | Plasmid repositories couldn’t be tracked and kept up to date. |
| Inefficient request fulfillment | Lack of a formal request system led to lost requests and insufficient detail in requests. Without a reliable plasmid inventory, certain requests were difficult to complete. |
Outcomes
| Centralized registration | Standardized lists of plasmids and other entities make data reliable and easily shared. |
|---|---|
| Streamlined request triaging | With Benchling Requests, teams generate greater throughput and higher quality products because they can easily access the information they need. |
| Generating R&D insights | Benchling Workflows empowers Intellia to identify the upstream entities that lead to successful batches. |
Powering breakthroughs for over 1,200 biotechnology companies, from startups to Fortune 500s
